---
id: shigella_061
category: organisms
tags: [shigella, bacillary-dysentery, bloody-diarrhea, HUS, reactive-arthritis, azithromycin]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Shigella (Bacillary Dysentery)

**Q:** What are the clinical features, complications (HUS, reactive arthritis), and treatment of shigellosis?

**A:**

**Microbiology:**
- **Gram-negative rods** (Enterobacterales family)
- **Four species:** S. dysenteriae (most severe), S. flexneri, S. boydii, S. sonnei (most common in US)
- Human-restricted pathogen (no animal reservoir)
- **Highly infectious:** 10-100 organisms can cause disease

**Epidemiology:**
- **~450,000 infections/year in US** (~38 deaths)
- Global: 188 million infections/year (developing countries)
- Transmission: Fecal-oral, person-to-person, contaminated food/water
- Risk groups: Children, MSM, travelers, daycare settings

---

**Pathophysiology:**

**Invasive Colitis:**
1. Invades colonic epithelium (M cells in Peyer's patches)
2. Multiplies intracellularly → lateral spread to adjacent epithelial cells
3. **Shiga toxin** production (especially S. dysenteriae type 1):
   - Inhibits protein synthesis (60S ribosomal subunit)
   - Causes endothelial damage
4. Result: **Inflammatory colitis** with mucosal ulceration

---

**Clinical Presentation:**

**Incubation:** 1-7 days (typically 1-3 days)

**Classic "Bacillary Dysentery":**

**Phases:**

**1. Watery Diarrhea (First 1-2 days):**
- High-volume watery stools
- Fever, cramping

**2. Dysentery (Days 2-5):**
- **Frequent small-volume bloody stools** with mucus ("currant jelly")
- **Severe abdominal cramps, tenesmus** (rectal spasm)
- **Fever** (common)
- **Fecal leukocytes** present (inflammatory diarrhea)

**Key Features:**
- **<10 WBC/hpf in stool → unlikely Shigella**
- **Bloody mucoid stools + tenesmus + fever** = classic triad

**Duration:** 5-7 days (self-limited if uncomplicated)

---

**Complications:**

**1. Hemolytic Uremic Syndrome (HUS):**

**Epidemiology:**
- **S. dysenteriae type 1** (Shiga toxin producer) → 13% develop HUS
- Most common in children <5 years
- Africa and Asia (epidemic dysentery)
- **Case-fatality rate ~36%** (leading cause of death in S. dysenteriae outbreaks)

**Pathophysiology:**
- Shiga toxin damages endothelium → thrombotic microangiopathy

**Triad:**
- **M**icroangiopathic hemolytic anemia (schistocytes)
- **T**hrombocytopenia
- **A**cute renal failure

**Management:**
- Supportive (dialysis if needed)
- Avoid **inappropriate antibiotics** (↑ toxin release → ↑ HUS risk)

**2. Reactive Arthritis (Post-Infectious Arthritis):**

**Epidemiology:**
- **S. flexneri** → 2% develop reactive arthritis
- HLA-B27 positive individuals (higher risk)

**Clinical Features:**
- Oligoarthritis 1-4 weeks post-infection
- Knees, ankles, feet (asymmetric)
- May have **Reiter's syndrome:** Arthritis + urethritis + conjunctivitis
- Self-limited (weeks to months), but can → chronic arthritis

**3. Bacteremia (Rare):**
- **S. dysenteriae, S. flexneri** (more invasive)
- High-risk: Malnutrition, HIV, young children
- ~7% mortality

**4. Other:**
- Toxic megacolon (rare)
- Seizures (children, febrile or toxin-mediated)
- Rectal prolapse (severe tenesmus)

---

**Diagnosis:**

**Stool Culture (Gold Standard):**
- Requires fresh stool (organism fragile)
- Selective media (MacConkey, XLD)
- Sensitivity ~60-70%

**PCR (Multiplex GI Panels):**
- More sensitive than culture
- Rapid (24h)
- Does NOT provide antibiotic susceptibilities

**Microscopy:**
- **Fecal leukocytes** present (>10 WBC/hpf)
- If <10 WBC/hpf → unlikely Shigella

---

**Treatment:**

**Antibiotic Indications:**

**Always Treat Shigella (Unlike Salmonella):**
- **Antibiotics shorten illness duration** (from 7 days → 2-3 days)
- **Reduce fecal shedding** (prevent transmission)
- **Decrease complications**

**1. First-Line Antibiotics (2024 Guidelines):**

| **Antibiotic** | **Dosing** | **Duration** | **Notes** |
|----------------|------------|--------------|-----------|
| **Azithromycin** (preferred) | 1g PO x1 (or 500 mg daily) | Single dose (or 3 days) | Preferred due to ↑ FQ resistance |
| **Ciprofloxacin** | 500 mg PO BID | 3 days | ↑ Resistance (3.7-70% globally) |
| **Levofloxacin** | 500 mg PO daily | 3 days | ↑ Resistance |
| **Ceftriaxone** (severe) | 2g IV daily | 5 days | If unable to take PO, severe illness |

**2. Resistance Patterns (2024):**

**High Resistance:**
- Ampicillin, TMP-SMX, tetracyclines → **NOT recommended**

**Emerging Resistance:**
- **Fluoroquinolones:** 3.7-70% resistance (varies by region)
- **Azithromycin:** 5-67% resistance (increasing)

**Strategy:**
- **Azithromycin preferred first-line** (lower resistance than FQ)
- If severe or high-risk (immunocompromised, children, elderly): Use antibiotics regardless
- Local susceptibility testing recommended

**3. Supportive Care:**
- Oral rehydration
- **Avoid anti-motility agents** (loperamide) → ↑ risk of toxic megacolon
- **Avoid inappropriate antibiotics early** (↑ toxin release → ↑ HUS risk with S. dysenteriae)

---

**Public Health:**

**Highly Contagious:**
- Exclude from daycare/school until diarrhea resolves
- Food handlers: 2 negative stool cultures before return to work
- Report to public health (notifiable disease)

---

**Comparison: Shigella vs Salmonella vs Campylobacter**

| **Feature** | **Shigella** | **Salmonella (NTS)** | **Campylobacter** |
|-------------|--------------|----------------------|-------------------|
| **Inoculum** | 10-100 (very low) | 10⁵-10⁶ (high) | 500 (moderate) |
| **Dysentery** | ✅ Classic (bloody mucoid) | Sometimes | Sometimes |
| **Tenesmus** | ✅ Prominent | Rare | Rare |
| **HUS Risk** | ✅ S. dysenteriae type 1 | Rare | Rare |
| **Reactive Arthritis** | ✅ S. flexneri (2%) | Yes (1-5%) | ✅ Common |
| **Antibiotics** | **Always treat** | Usually NOT | Usually NOT |
| **Bacteremia** | Rare | 5-10% | Rare |

---

**Mnemonic: "SHIGELLA = Severe Hemorrhagic Inflammatory GI with Extra Leukocytes, Low inoculum, Always treat"**
- **S**evere dysentery (bloody mucoid stools)
- **H**US (S. dysenteriae type 1)
- **I**nvasive colitis
- **G**I tenesmus (rectal spasm)
- **E**xtra leukocytes (fecal WBCs >10/hpf)
- **L**ow inoculum (10-100 organisms)
- **L**ow inoculum
- **A**lways treat (antibiotics shorten illness, reduce shedding)

**Mnemonic: "Dysentery = Dx S. dysenteriae → HUS"**
- **D**ysentery
- **S**. dysenteriae type 1
- **H**US (13% of cases)

**Clinical Pearls:**
- **Always treat Shigella with antibiotics** (unlike Salmonella or Campylobacter)
- **Azithromycin preferred** over fluoroquinolones (lower resistance, single-dose option)
- **Bloody mucoid stools + tenesmus + fever** = think Shigella
- **<10 WBC/hpf in stool → unlikely Shigella** (inflammatory diarrhea expected)
- **Very low inoculum (10-100 organisms)** → highly contagious, person-to-person spread
- **S. dysenteriae type 1** → epidemic dysentery in developing countries → HUS risk 13%
- **S. flexneri** → reactive arthritis (2%), especially HLA-B27 positive
- Avoid loperamide (anti-motility agents) → risk of toxic megacolon
- **Do NOT use ampicillin, TMP-SMX** (widespread resistance)
- Unlike Salmonella, antibiotics shorten illness and reduce transmission

**Media:** None

**Sources:** [CDC 2024 - Shigella treatment], [CDC 2024 - Clinical overview shigellosis], [PMC 2018 - Guidelines for dysentery treatment], [PMC 2019 - Antibiotic therapy for Shigella dysentery], [Medscape 2024 - Shigella medication], [MSD Manual 2024 - Shigellosis], [MSF Medical Guidelines - Shigellosis], [ScienceDirect 2024 - Azithromycin resistance in Shigella]
